Alerta

COMPOSITIONS AND METHODS FOR REDUCING AMYLOID BETA FORMATION AND COMPOSITION THEREFORE

Resumen de: EP4741012A2

0001 The present invention provides a pharmaceutical composition for use in treating Alzheimer's Disease (AD), the composition comprising mirodenafil or a pharmaceutically acceptable salt, solvate, and hydrate thereof, wherein the composition suppresses DKK-1 to activate Wnt Signaling to restore Synaptic Plasticity and suppresses Positive Feedback Loop of Aβ production to reduce formation of APP (Amyloid precursor Protein) and Aβ accumulation.

CPG OLIGODEOXYNUCLEOTIDE CAPABLE OF REGULATING IMMUNE FUNCTION OF BODY AND USE THEREOF

Resumen de: EP4741506A1

The present disclosure discloses a plurality of CpG-containing oligodeoxynucleotides (ODNs) with immunomodulatory properties, and use thereof. The oligodeoxynucleotides provided in present disclosure differ in sequence and structure from the design concept of conventional Type A CpG ODNs, reflecting their own complex drug-forming principles and overcoming the problems of conventional Type A CpG in drug development. The oligodeoxynucleotides exhibit excellent immunomodulatory activity both in vitro and in vivo, and they can stimulate the production of type I, II, and III interferons, upregulate Th1-type immune responses, and inhibit Th2-type and Th17-type inflammatory responses. Therefore, the oligodeoxynucleotides can: prevent and treat allergic diseases caused by Th2-type immune responses, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophilia, and Th17-related diseases; can prevent and treat infections and transmission of respiratory or non-respiratory pathogens, including viruses, bacteria, fungi, and parasites; can improve the immune levels of the elderly population and individuals with immunodeficiency; can transform "cold tumors" into "hot tumors" and improve the effectiveness of cancer immunotherapy; can prevent and treat central nervous system diseases related to immune dysfunction, such as Alzheimer's disease; and can be applied to other diseases related to immune dysregulation.

2-(1H-INDOL-4-YL)METHYL)-ISOINDOLINE DERIVATIVES AS FACTOR B INHIBITORS

Resumen de: WO2025008453A1

The present invention relates to compounds (I) possessing an indole moiety linked to an isoindoline moiety, to compounds having similar core structures, and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present invention further relates to methods of synthesising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by Factor B inhibition.

2-(1H-INDOL-4-YL)METHYL)2H-INDAZOLE DERIVATIVES AS FACTOR B INHIBITORS

Resumen de: WO2025008451A1

The present invention relates to compounds of formula (I) possessing an indole moiety linked to an indazole moiety, to compounds having similar core structures, and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present invention further relates to methods of synthesising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by Factor B inhibition.

DIAGNOSIS OF DEMENTIA BY VASCULAR MAGNETIC RESONANCE IMAGING

Resumen de: EP4741014A2

0001 A method of diagnosing a likelihood of onset or progression of Alzheimer's disease and related dementias (ADRD) in a subject is provided. The method requires determining vascularization changes in different regions of the brain on the basis of a quantitative cerebral blood volume (qCBV) map of the subject's brain. The qCBV is obtained from one or more quantitative ultrashort time-to-echo contrast-enhanced (QUTE-CE) MRI images of the brain. A method of treating a subject for ADRD is provided. Diagnostic markers for onset and progression of Alzheimer's disease are also provided.

MODIFIED RELEASE TOLCAPONE FORMULATIONS

Resumen de: US20260124146A1

0000 Modified release tablet dosage forms comprising tolcapone are disclosed. The tablet dosage forms provide a pulsed, pH dependent release profile of tolcapone to both the gastric space and the small intestine. Methods of treating or preventing a disease selected from transthyretin amyloidosis (ATTR), Parkinson's Disease and obsessive compulsive disorder using said dosage forms are provided.

METHODS FOR TREATING EARLY ALZHEIMER’S DISEASE

Resumen de: US20260124236A1

Provided herein are methods for treating early Alzheimer's Disease using hydroxypropyl β-cyclodextrin compositions.

COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS

Resumen de: US20260124278A1

0000 Long-acting glucagon like peptide 1 receptor agonists (GLP-1r agonists) reduce and inhibit pathological processes that give rise to long-term neurological impairment. A biotinylated and/or lipidated GLP-1r agonist analogs with enhanced enzymatic stability needed for gastrointestinal absorption, improved bioavailability and pharmacokinetics are described. In preferred embodiments, the GLP-1r agonist analogs have the amino acid sequence of any one of SEQ ID NOs: 9-35. The compositions are typically administered via oral or parenteral routes. The compositions are particularly suited for treating, alleviating, and/or preventing one or more neurological diseases or disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD). Methods of treating a human subject having AD or PD or at risk of AD or PD are provided.

BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS

Resumen de: US20260124195A1

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34

Resumen de: US20260125460A1

The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.

Composition for preventing or treating Parkinson's disease comprising brain endothelial cell-derived nanovesicles as an active ingredient

Resumen de: KR20260062161A

본 발명은 뇌 내피세포 유래 나노베지클을 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 조성물에 관한 것으로, 더 상세하게는 IL-4로 표면 장식된 뇌 내피세포 유래 나노베지클을 유효성분으로 포함하는 파킨슨병 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 IL-4가 표면 장식된 뇌 내피세포 유래 나노베지클은 혈액-뇌 장벽을 효과적으로 통과하여, 뇌 내피세포 활성을 증가시키고, 도파민성 신경세포의 증식을 유도하며, 도파민성 신경세포 손상을 억제하고, 뇌 미세아교세포의 염증성 상태에서 항염증성 상태로의 재분극을 유도하는 바, 파킨슨 병의 예방, 개선, 치료에 유용한 치료제로 활용 가능한 장점이 있다.

METHODS AND COMPOSITIONS FOR TREATING AND MANAGING ALZHEIMER'S DISEASE

Resumen de: WO2026096493A1

The present disclosure provides methods of diagnosing, characterizing, or treating diseases (e.g., Alzheimer's Disease) associated with phosphorylated tau proteins, including p-tau217 and p-tau243, in subjects in need thereof.

PYRAZOLONE COMPOUNDS FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASE

Resumen de: WO2026097040A2

Pyrazolone compounds, pharmaceutical compositions comprising the same, and methods of using the same are disclosed herein. The disclosed compounds may be used for treatment of neurodegenerative diseases and/or disorders, such as Alzheimer's disease.

SMALL MOLECULE INHIBITORS OF DYRK1/CLK AND USES THEREOF

Resumen de: WO2026096717A1

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazo-pyridine structure, or compounds having a pyridinyl-purine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and are useful as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes (e.g., any type or form of diabetes, including type-1 or type-2), autoimmune diseases, inflammatory disorders (e.g., airway inflammation), cancer (e.g., glioblastoma, prostate cancer), diabetes, and other diseases.

ANTI-N3PGLU Aβ ANTIBODY AND USE THEREOF

Resumen de: WO2026092407A1

An anti-N3pGlu Aβ antibody, a nucleic acid encoding same and the use thereof. The thermostability and immunogenicity in clinical use of various anti-N3pGlu Aβ antibodies have attracted widespread attention in the development of N3pGlu Aβ antibodies. Clinically, the presence of anti-drug antibodies is correlated to some extent with a shortened half-life thereof. Compared with an antibody without modification, a modified antibody exhibits higher yield and lower immunogenicity, and have better application prospects in the treatment of Alzheimer's disease.

Methods and Dosing Regimens for Preventing or Delaying Onset of Alzheimer's Disease and Other Forms of Dementia and Mild Cognitive Impairment

Resumen de: US20260126455A1

0000 Methods and dosing regimens using alpha 7 acetylcholine nicotine receptor binding agents are provided to prevent or inhibit intracellular accumulation of amyloid in cells leading to inhibition or prevention of neuronal cell death. In addition, these methods and dosing regimens are coupled with methods and dosing regimens to reduce and/or prevent blood-brain barrier leakage of vascular-derived amyloid into the brain and/or methods and dosing regimens to reduce and/or prevent neuroinflammation to prevent and/or inhibit the progression of Alzheimer's disease and other forms of dementia and mild cognitive impairment. Also provided are methods for identifying individuals for this treatment.

HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS

Resumen de: US20260125364A1

0000 The present invention provides, in part, compounds of Formula I: 0000 0000 and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, Tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, SLE, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.

COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING DISEASE CAUSED BY PROTEIN NITRATION COMPRISING PEPTIDE WITH TERMINAL TYROSINE AS EFFECTIVE COMPONENT

Resumen de: EP4736869A2

0001 According to the present invention, the peptide with terminal tyrosine has an excellent effect on inhibiting protein nitration and also an excellent effect on preventing, ameliorating, or treating disease symptoms in chronic immobilization stress-induced depression/cognitive impairment model, Alzheimer's disease model, epileptic seizure model, stroke model, type 2 diabetes model, acute renal failure model, or hyperammonemia model.

SUBSTITUTED PYRIDAZINE COMPOUNDS AS INHIBITORS OF NLRP3 ACTIVITY AND THERAPEUTIC USES THEREOF

Resumen de: WO2025006681A2

This application discloses novel substituted pyridazine compounds and analogues, their preparation, pharmaceutical compositions comprising them, and their therapeutic uses as medicaments for treating diseases or disorders associated with modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3, or inhibition of the activation of NLRP3 or related components of the inflammatory process.

LEVODOPA-BENSERAZIDE HYDROCHLORIDE COMPOSITION AND PREPARATION THEREFOR

Resumen de: EP4736851A1

0001 Provided in the present invention are a pharmaceutical composition used for treating Parkinson's disease and a preparation method therefor. Tablets prepared from the pharmaceutical composition have better stability, and involve a simple production process, thus facilitating commercial production.

SIRNA INHIBITING EXPRESSION OF AMYLOID PRECURSOR PROTEIN (APP) GENE, DRUG, AND USE

Resumen de: MX2026003382A

Provided are an siRNA inhibiting the expression of an amyloid precursor protein (APP) gene in a human cell, a polypeptide-oligonucleotide drug, and a use. The siRNA has good APP expression inhibitory activity, and a suitable modification is made to the siRNA to improve the silencing capability against a target and reduce off-target activity. The siRNA and a conjugate thereof are expected to be applied for clinically preventing and treating an APP target-related disease such as cerebral amyloid angiopathy (CAA), early-onset familial Alzheimer's disease (EOFAD), or Alzheimer's disease (AD).

ANTI-TDP-43 ANTIBODIES AND USES THEREOF

Resumen de: MX2026003216A

The present disclosure provides antibodies that specifically bind to human TDP-43 and methods of using these antibodies to treat patients with TDP-43-related diseases, including Amyotrophic Lateral Sclerosis (ALS).

CRYSTALLINE FORMS OF 6-(6-(((1R,2R,3S,5S)-2-FLUORO-9-AZABICYCLO3.3.1NONAN-3-YL)(METHYL)AMINO)PYRIDAZIN-3-YL)-2-METHYLBENZODOXAZOL-5-OL, A SPLICING MODULATOR FOR THE TREATMENT OF HUNTINGTON'S DISEASE

Resumen de: MX2026000162A

Described herein are crystalline forms of 6-(6-(((1R,2R,3S,5S)-2-fluoro-9-azabicyclo3.3.1nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzodoxazol-5-ol (compound A), a small molecule splicing modulator (SMSM) of mRNA, such as pre-mRNA, encoded by genes, for the treatment of Huntington's disease.

NEUROFILAMENT PROTEIN FOR GUIDING THERAPEUTIC INTERVENTION IN AMYOTROPHIC LATERAL SCLEROSIS

Resumen de: MX2026003864A

In one aspect, the invention provides a method for alleviating a symptom in a patient with amyotrophic lateral sclerosis, comprising administering an efficacious therapeutic that is efficacious to the patient, the efficacious therapeutic, when administered to the patient, resulting in a level of a neurofilament protein in a biological sample of the patient that is lower than a level of neurofilament protein in a patient with amyotrophic lateral sclerosis not administered the therapeutic. In some embodiments, the patient is currently being administered with or has formerly been administered with either a non-efficacious therapeutic or a therapeutic that is different than the efficacious therapeutic.

AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF

Nº publicación: MX2026000485A 04/05/2026

Solicitante:

INCRELAND [CN]
INCRELAND

Resumen de: MX2026000485A

Disclosed in the present invention are an aromatic compound, a pharmaceutical composition containing same, and a use thereof. The aromatic compound is a compound having formula (I), and can effectively degrade IRAK4 or otherwise inhibit IRAK4 activity. The compound and the pharmaceutical composition of the present invention have good prospects for application in IRAK4-mediated diseases including immune diseases, tumors, Alzheimer's disease, and fibrotic diseases, providing a new choice for clinically screening and/or preparing drugs for diseases associated with IRAK4 activity.